Back to discover
Drug

Estradiol

Approved · FDA
ClassEstrogen receptor alpha agonistEmerging researchLate-stage developmentRising momentum
Also known as 17 Beta-Estradiol, 17-beta estradiol, 17Beta-estradiol, 17beta oestradiol+63 more

17 Beta-Estradiol, 17-beta estradiol, 17Beta-estradiol, 17beta oestradiol, Alora, Bijuva, CLIMARA, Climara Pro, Climaval, Combipatch, Compudose, Delatestadiol, Delestrogen, Dep Androgyn, Depo-Estradiol, Depo-Testadiol, Depotestogen, Divigel, Dotti, Duo-Cyp, Dura-Dumone, Duratestrin, E2 - estradiol, ESTRADIOL 17-BETA, Elestrin, Elleste Solo, Esclim, Estra-Testrin, Estrace, Estraderm, Estradiol Benzoate, Estradiol Cypionate, Estradiol Hemihydrate, Estradiol Vaginal Insert, Estradiol Valerate, Estradiol-17beta, Estrasorb, Estring, Estrogel, Evamist, Fempatch, Femring, Femtrace, Gynodiol, Imvexxy, Lunelle, Lyllana, Menostar, Minivelle, Myfembree, OESTROGEL, Oestradiol, Oestradiol Implants, PROGYNOVA, Prefest, Revalor, Synovex, Synovex C, Synovex H, Synovex S, Vagifem, Vivelle, Yuvafem, Zumenon, beta-Estradiol, cis-Estradiol, Estradiolum.

17
Research papers
18
Active clinical trials
Estrogen receptor
Primary target
18
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Postpartum Vaginal Estrogen for Sexual Function in Breastfeeding Patients: A Randomized Controlled Trial

Clinical trial2026-07-23Results expected Q4 2026 · ClinicalTrials.gov

Effects of Estrogen on Muscle Gain During 12-weeks of Exercise in Post-menopausal Women

Clinical trial2026-06-01Results expected Q3 2027 · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Estradiol
Aliases & brands
17 Beta-Estradiol17-beta estradiol17Beta-estradiol17beta oestradiolAloraBijuvaCLIMARAClimara ProClimavalCombipatchCompudoseDelatestadiolDelestrogenDep AndrogynDepo-EstradiolDepo-TestadiolDepotestogenDivigelDottiDuo-CypDura-DumoneDuratestrinE2 - estradiolESTRADIOL 17-BETAElestrinElleste SoloEsclimEstra-TestrinEstraceEstradermEstradiol BenzoateEstradiol CypionateEstradiol HemihydrateEstradiol Vaginal InsertEstradiol ValerateEstradiol-17betaEstrasorbEstringEstrogelEvamistFempatchFemringFemtraceGynodiolImvexxyLunelleLyllanaMenostarMinivelleMyfembreeOESTROGELOestradiolOestradiol ImplantsPROGYNOVAPrefestRevalorSynovexSynovex CSynovex HSynovex SVagifemVivelleYuvafemZumenonbeta-Estradiolcis-EstradiolEstradiolum
RxNorm CUI
4083
ChEMBL ID
CHEMBL135
ATC codes
G03CA03
UNII
4TI98Z838E
Primary mechanism
Estrogen receptor alpha agonist
Regulatory jurisdictions
fda

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Estrogen receptor
ESR1 · P03372
AGONISTEstrogen receptor alpha agonist

Regulatory timeline

18 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2000-02-24
Latest approval
2006-07-20
Authorities
FDA
Total events
18
fdaU.S. Food and Drug Administration· 18 events
2026-06-08Label change
Label change: ESTRADIOL (ANDA075182)
Evidence ↗
2026-06-08Label change
Label change: ESTRADIOL (ANDA075182)
Evidence ↗
2026-06-08Label change
Label change: ESTRADIOL (ANDA075182)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

168 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
168
registered trials across all phases
LATEST COMPLETION 2025
18
Active studies
14
Recruiting
114
Late-stage (III+)
99
Completed
51
Discontinued
PHASE DISTRIBUTIONn = 168
Early Phase 16Phase 111Phase 1 / 24Phase 233Phase 2 / 34Phase 331Phase 438Phase N / A41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

17 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19902025
Most influential

Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 1992 · 936 cites

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

The New England journal of medicine · 2018 · 885 cites

Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 1990 · 818 cites

Estrogen stimulates a transient increase in the number of new neurons in the dentate gyrus of the adult female rat.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 1999 · 696 cites

Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 1994 · 491 cites
Recent papers
Major research themes8
Estradiol4Testosterone4Gonadal Steroid Hormones3Inflammation2Sex Hormone-Binding Globulin2Basic Helix-Loop-Helix Leucine Zipper Transcription Factors1Bone Density1C-Reactive Protein1
Journals, researchers & institutions
Top journals
  • The Journal of neuroscience : the official journal of the Society for Neuroscience4
  • The New England journal of medicine2
  • Annals of internal medicine1
  • BMC endocrine disorders1
  • Cell death and differentiation1
  • Clinical journal of the American Society of Nephrology : CJASN1
Leading researchers
  • McEwen BS3
  • Woolley CS3
  • Gould E2
  • Adams RJ1
  • Ahmed A1
  • André F1
  • Antonio L1
  • Balk SP1
Leading institutions
free-text, unnormalised
  • Baylor College of Medicine3
  • Laboratory of Neuroendocrinology3
  • School of Medicine2
  • Aarhus University Hospital1
  • Adelaide Institute for Sleep Health1
  • Amsterdam University Medical Centers1

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 13 of the same disease areas as Estradiol in the shared literature.

13 shared diseases9 shared papers

Acts on the same molecular target as Estradiol, with 2 overlapping disease areas.

Shared target2 shared diseases1 shared paper

Studied across 6 of the same disease areas as Estradiol in the shared literature.

6 shared diseases4 shared papers

Studied across 7 of the same disease areas as Estradiol in the shared literature.

7 shared diseases1 shared paper

Studied across 6 of the same disease areas as Estradiol in the shared literature.

6 shared diseases1 shared paper

Studied across 6 of the same disease areas as Estradiol in the shared literature.

6 shared diseases1 shared paper

Studied across 3 of the same disease areas as Estradiol in the shared literature.

3 shared diseases2 shared papers

Studied across 3 of the same disease areas as Estradiol in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.